{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:44:53Z","timestamp":1792511093368,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["1UG1DA050077"],"award-info":[{"award-number":["1UG1DA050077"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Braeburn Pharmaceuticals, Inc."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jsat.2020.108241","type":"journal-article","created":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T11:51:51Z","timestamp":1607687511000},"page":"108241","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail"],"prefix":"10.1016","volume":"128","author":[{"given":"Michael S.","family":"Gordon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon Gwin","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.","family":"Blue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank J.","family":"Vocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc J.","family":"Fishman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean M.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Couvillion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Wenzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha L.","family":"Danner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel K.","family":"Jarvis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2020.108241_bb0005","series-title":"Statistical modelling in GLIM 4","author":"Aitkin","year":"2005"},{"issue":"2","key":"10.1016\/j.jsat.2020.108241_bb0010","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1007\/s12325-016-0472-9","article-title":"Pharmacokinetic evaluation of once-weekly and once-monthly buprenorphine subcutaneous injection depots (CAM2038) versus intravenous and sublingual buprenorphine in healthy volunteers under naltrexone blockade: An open-label Phase 1 study","volume":"34","author":"Albayaty","year":"2017","journal-title":"Advances in Therapy"},{"key":"10.1016\/j.jsat.2020.108241_bb0015","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.addbeh.2018.02.024","article-title":"Criminal justice continuum for opioid users at risk of overdose","volume":"86","author":"Brinkley-Rubinstein","year":"2018","journal-title":"Addictive Behaviors"},{"key":"10.1016\/j.jsat.2020.108241_bb0020","series-title":"Drug use, dependence, and abuse among state prisoners and jail inmates, 2007\u20132009","author":"Bronson","year":"2017"},{"issue":"2","key":"10.1016\/j.jsat.2020.108241_bb0025","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1001\/jama.2008.976","article-title":"Treating drug abuse and addiction in the criminal justice system: Improving public health and safety","volume":"301","author":"Chandler","year":"2009","journal-title":"Journal of the American Medical Association"},{"key":"10.1016\/j.jsat.2020.108241_bb0030","series-title":"Prisons and drugs: A global review of incarceration, drug use and drug services","author":"Dolan","year":"2007"},{"key":"10.1016\/j.jsat.2020.108241_bb0035","series-title":"Successful randomized trials: A handbook for the 21st century","year":"2009"},{"key":"10.1016\/j.jsat.2020.108241_bb0040","series-title":"The essential guide to effect sizes: Statistical power, meta-analysis, and the interpretation of research results","author":"Ellis","year":"2010"},{"issue":"4","key":"10.1016\/j.jsat.2020.108241_bb0045","first-page":"472","article-title":"Prescribing opioid replacement therapy in US correctional settings","volume":"45","author":"Farahmand","year":"2017","journal-title":"The Journal of the American Academy of Psychiatry and the Law"},{"issue":"2","key":"10.1016\/j.jsat.2020.108241_bb0050","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1360-0443.2006.01316.x","article-title":"Substance abuse and dependence in prisoners: A systematic review","volume":"101","author":"Fazel","year":"2006","journal-title":"Addiction"},{"issue":"1","key":"10.1016\/j.jsat.2020.108241_bb0055","first-page":"1","article-title":"Opioid addiction and criminal justice systems: Opportunities to break the cycle of incarceration","volume":"38","author":"Fox","year":"2015","journal-title":"SGIM Forum"},{"issue":"1","key":"10.1016\/j.jsat.2020.108241_bb0060","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/08897077.2011.611460","article-title":"Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): Availability, barriers, and intentions","volume":"33","author":"Friedmann","year":"2012","journal-title":"Substance Abuse"},{"issue":"3","key":"10.1016\/j.jsat.2020.108241_bb0065","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/ADM.0b013e31814b8880","article-title":"Buprenorphine-naloxone treatment for pre-release opioid-dependent inmates in Puerto Rico","volume":"1","author":"Garcia","year":"2007","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2020.108241_bb0070","series-title":"Economic evaluation in clinical trials","author":"Glick","year":"2014"},{"key":"10.1016\/j.jsat.2020.108241_bb0075","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.drugalcdep.2014.05.011","article-title":"A randomized controlled trial of prison-initiated buprenorphine: Prison outcomes and community treatment entry","volume":"142","author":"Gordon","year":"2014","journal-title":"Drug and Alcohol Dependence"},{"issue":"8","key":"10.1016\/j.jsat.2020.108241_bb0080","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1360-0443.2008.002238.x","article-title":"A randomized clinical trial of methadone maintenance for prisoners: Findings at 6 months post-release","volume":"103","author":"Gordon","year":"2008","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2020.108241_bb0085","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.drugalcdep.2016.11.037","article-title":"A randomized clinical trial of buprenorphine for prisoners: Findings at 12-months post-release","volume":"172","author":"Gordon","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2020.108241_bb0090","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jsat.2017.04.008","article-title":"Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid use disorder","volume":"78","author":"Haasen","year":"2017","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"329","key":"10.1016\/j.jsat.2020.108241_bb0095","first-page":"1","article-title":"Drug overdose deaths in the United States, 1999\u20132017","volume":"November 2018","author":"Hedegaard","year":"2018","journal-title":"National Center for Health Statistics Data Brief"},{"issue":"3","key":"10.1016\/j.jsat.2020.108241_bb0100","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/YCO.0b013e3282fc985c","article-title":"Drug use and health among prison inmates","volume":"21","author":"Kanato","year":"2008","journal-title":"Current Opinion in Psychiatry"},{"key":"10.1016\/j.jsat.2020.108241_bb0105","series-title":"Opioid substitution treatment in custodial settings","author":"Kastelic","year":"2009"},{"key":"10.1016\/j.jsat.2020.108241_bb0110","series-title":"Lowinson & Ruiz\u2019s substance abuse: A comprehensive textbook","first-page":"881","article-title":"Incarcerated populations","author":"Kinlock","year":"2011"},{"issue":"3","key":"10.1016\/j.jsat.2020.108241_bb0115","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jsat.2009.03.002","article-title":"A randomized clinical trial of methadone maintenance for prisoners: Results at 12 months postrelease","volume":"37","author":"Kinlock","year":"2009","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2020.108241_bb0120","series-title":"Heroin addiction: Prevalence, treatment approaches and health consequences","first-page":"127","article-title":"Pharmacotherapy for incarcerated individuals with histories of heroin addiction","author":"Kinlock","year":"2015"},{"issue":"12","key":"10.1016\/j.jsat.2020.108241_bb0125","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1377\/hlthaff.2017.0890","article-title":"Only one in twenty justice-referred adults in specialty treatment for opioid use receive methadone or buprenorphine","volume":"36","author":"Krawczyk","year":"2017","journal-title":"Health Affairs"},{"issue":"6","key":"10.1016\/j.jsat.2020.108241_bb0130","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/add.12894","article-title":"Opioid treatment at release from jail using extended-release naltrexone: A pilot proof-of-concept randomized effectiveness trial","volume":"110","author":"Lee","year":"2015","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2020.108241_bb0135","series-title":"The NSDUH report: Trends in heroin use in the United States: 2002 to 2013","first-page":"1","author":"Lipari","year":"2015"},{"key":"10.1016\/j.jsat.2020.108241_bb0140","series-title":"SAS for mixed models","author":"Littell","year":"2006"},{"issue":"6","key":"10.1016\/j.jsat.2020.108241_bb0145","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: A randomized clinical trial","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Internal Medicine"},{"issue":"1\u20133","key":"10.1016\/j.jsat.2020.108241_bb0150","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.drugalcdep.2008.08.006","article-title":"Buprenorphine and methadone maintenance in jail and post-release: A randomized clinical trial","volume":"99","author":"Magura","year":"2009","journal-title":"Drug and Alcohol Dependence"},{"issue":"1","key":"10.1016\/j.jsat.2020.108241_bb0155","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1080\/08897077.2011.609446","article-title":"A randomized trial of methadone initiation prior to release from incarceration","volume":"33","author":"McKenzie","year":"2012","journal-title":"Substance Abuse"},{"issue":"2","key":"10.1016\/j.jsat.2020.108241_bb0160","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/ADM.0000000000000381","article-title":"Feasibility and effectiveness of continuing methadone maintenance treatment during incarceration compared to forced withdrawal","volume":"12","author":"Moore","year":"2018","journal-title":"Journal of Addiction Medicine"},{"key":"10.1016\/j.jsat.2020.108241_bb0165","series-title":"Multiple analyses in clinical trials: Fundamentals for investigators","first-page":"241","author":"Moy\u00e9","year":"2003"},{"issue":"1\u20132","key":"10.1016\/j.jsat.2020.108241_bb0170","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.drugalcdep.2009.06.015","article-title":"Methadone and buprenorphine prescribing and referral practices in US prison systems: Results from a nationwide survey","volume":"105","author":"Nunn","year":"2009","journal-title":"Drug and Alcohol Dependence"},{"issue":"34","key":"10.1016\/j.jsat.2020.108241_bb0175","doi-asserted-by":"crossref","first-page":"897","DOI":"10.15585\/mmwr.mm6634a2","article-title":"Trends in deaths involving heroin and synthetic opioids excluding methadone, and law enforcement drug product reports, by census region\u2014United States, 2006\u20132015","volume":"66","author":"O\u2019Donnell","year":"2017","journal-title":"Morbidity and Mortality Weekly Report"},{"issue":"3","key":"10.1016\/j.jsat.2020.108241_bb0180","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/jurban\/jti072","article-title":"Attitudes and practices regarding the use of methadone in US state and federal prisons","volume":"82","author":"Rich","year":"2005","journal-title":"Journal of Urban Health"},{"issue":"9991","key":"10.1016\/j.jsat.2020.108241_bb0185","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S0140-6736(14)62338-2","article-title":"Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: A randomised, open-label trial","volume":"386","author":"Rich","year":"2015","journal-title":"The Lancet"},{"issue":"6","key":"10.1016\/j.jsat.2020.108241_bb0190","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/BF01068419","article-title":"A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability","volume":"15","author":"Schuirmann","year":"1987","journal-title":"Journal of Pharmacokinetics and Biopharmaceutics"},{"issue":"1","key":"10.1016\/j.jsat.2020.108241_bb0195","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/QAI.0000000000001759","article-title":"Extended-release naltrexone improves viral suppression among incarcerated persons living with HIV and alcohol use disorders transitioning to the community: Results from a double-blind, placebo-controlled trial","volume":"79","author":"Springer","year":"2018","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.jsat.2020.108241_bb0200","series-title":"1999 Proceedings of the Biopharmaceutical Section","first-page":"15","article-title":"Mixed model procedures to assess power, precision, and sample size in the design of experiments","author":"Stroup","year":"1999"},{"issue":"1","key":"10.1016\/j.jsat.2020.108241_bb0205","first-page":"14","article-title":"The Key Extended Entry Program (KEEP): A methadone treatment program for opiate-dependent inmates","volume":"68","author":"Tomasino","year":"2001","journal-title":"The Mount Sinai Journal of Medicine, New York"},{"issue":"13","key":"10.1016\/j.jsat.2020.108241_bb0210","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1056\/NEJMra1507771","article-title":"Opioid abuse in chronic pain\u2014Misconceptions and mitigation strategies","volume":"374","author":"Volkow","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"2\u20133","key":"10.1016\/j.jsat.2020.108241_bb0215","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1080\/10550887.2015.1059217","article-title":"Addiction treatment within US correctional facilities: Bridging the gap between current practice and evidence-based care","volume":"34","author":"Wakeman","year":"2015","journal-title":"Journal of Addictive Diseases"},{"issue":"9","key":"10.1016\/j.jsat.2020.108241_bb0220","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1001\/jamapsychiatry.2017.1874","article-title":"Effect of buprenorphine weekly depot (CAM2038) and hydromorphone blockade in individuals with opioid use disorder: A randomized clinical trial","volume":"74","author":"Walsh","year":"2017","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1016\/j.jsat.2020.108241_bb0225","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jsat.2013.02.005","article-title":"Initiation of buprenorphine during incarceration and retention in treatment upon release","volume":"45","author":"Zaller","year":"2013","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.jsat.2020.108241_bb0230","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/19466315.2016.1225594","article-title":"Sample size calculation for comparing two Poisson or negative binomial rates in noninferiority or equivalence trials","volume":"9","author":"Zhu","year":"2017","journal-title":"Statistics in Biopharmaceutical Research"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547220304980?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547220304980?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:53:23Z","timestamp":1760039603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547220304980"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":46,"alternative-id":["S0740547220304980"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2020.108241","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2020.108241","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108241"}}